SEARCH

SEARCH BY CITATION

Referencias bibliográficas

  • 1
    Sarazzin C, Kieffer TL, Bartels D, Hanzeika B, Muh U, Welker M, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007;132:1767-1777.
  • 2
    Jacobson IM, McHutchinson JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-2416.
  • 3
    Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-1206.
  • 4
    Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
  • 5
    Jacobson IM, Catlett I, Marcellin P, Bzowej NH, Muir AJ, Adda A, et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial [abstract]. J Hepatol 2011;54:S542.
  • 6
    Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski M, et al. IL28B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with boceprevir (BOC) combination therapy [abstract]. J Hepatol 2011;54:S6.
  • 7
    Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-2428.